A Repeat Ascending Dosing Study of the Safety and Clinical Activity of R-3750 in Patients With Mild to Moderate COPD

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

December 31, 2027

Conditions

COPD (Chronic Obstructive Pulmonary Disease)COPD ExacerbationCOPD Exacerbation Acute

Interventions

DRUG

R-3750

R-3750 DP; Lactococcus lactis expressing Surface Layer Protein A (SlpA)

All Listed Sponsors

lead

Rise Therapeutics LLC

INDUSTRY